2. Immunology/Inflammation
  3. PGE synthase
  4. Zomepirac sodium salt

Zomepirac sodium salt  (Synonyms: McN-2783-21-98)

Cat. No.: HY-B0890 Purity: 99.63%
COA
SDS
Handling Instructions Technical Support

Zomepirac sodium salt (McN-2783-21-98) is an orally active prostaglandin synthetase inhibitor. Zomepirac sodium salt blocks prostaglandin synthesis and inhibits Collagen (HY-P72147)- or Epinephrine (HY-B0447)-induced platelet aggregation. Zomepirac sodium salt can be used for the research of postoperative pain and osteoarthritis.

For research use only. We do not sell to patients.

Zomepirac sodium salt

Zomepirac sodium salt Chemical Structure

CAS No. : 64092-48-4

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
50 mg In-stock
100 mg In-stock
500 mg In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Zomepirac sodium salt:

Zomepirac sodium salt Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Zomepirac sodium salt (McN-2783-21-98) is an orally active prostaglandin synthetase inhibitor. Zomepirac sodium salt blocks prostaglandin synthesis and inhibits Collagen (HY-P72147)- or Epinephrine (HY-B0447)-induced platelet aggregation. Zomepirac sodium salt can be used for the research of postoperative pain and osteoarthritis[1][2][3][4].

In Vitro

Zomepirac sodium salt potently inhibits prostaglandin synthesis in homogenised bovine seminal vesicles[3].
Zomepirac sodium salt potently inhibits Collagen (HY-NP003)-induced aggregation of human platelets in vitro[3].
Zomepirac (0.1-10 μg/mL) sodium salt is 98.5% bound to human plasma albumin in vitro[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Zomepirac sodium salt Related Antibodies
In Vivo

Zomepirac (p.o.) sodium salt exhibits potent non-narcotic analgesic activity in the Acetylcholine-induced writhing test in mice, with an oral ED50 of 0.84 mg/kg, and lacks narcotic-like activity in mouse tail pinch and hot plate tests[3].
Zomepirac (5 mg/kg; p.o.; 3 times daily; 3 days) sodium salt shows no physical dependence liability in the mouse Naloxone (HY-17417A) challenge jumping test[3].
Zomepirac (p.o.) sodium salt exhibits potent acute anti-inflammatory activity in the Carrageenan (HY-125474)-induced paw oedema test in rats, with an oral ED50 of 0.15 mg/kg[3].
Zomepirac (p.o.) sodium salt exhibits anti-inflammatory activity in the acute adjuvant-induced arthritis test in rats, with an oral ED50 of 3.9 mg/kg[3].
Zomepirac (p.o.) sodium salt exhibits analgesic activity in the chronic adjuvant-induced arthritis test in rats, with an oral ED50 of 16.6 mg/kg[3].
Zomepirac (p.o.) sodium salt has ulcerogenic activity in Rattus norvegicus rats, with an oral median ulcerogenic dose (UD50) of 13.9 mg/kg[3].
Zomepirac (0.3-3 mg/kg; i.v.) sodium salt reduces cerebrospinal fluid prostaglandin E2 concentrations by ~96% in conscious cats, with effects lasting up to 5 days[3].
Zomepirac (2-6 mg/kg; i.v.) sodium salt substantially reduces spinothalamic tract cell responses to nociceptive stimuli in anaesthetised rhesus monkeys[3].
Zomepirac (20 mg/kg; i.v.) sodium salt has minimal impact on renal haemodynamics and function in anaesthetised rhesus monkeys[3].
Zomepirac (10-40 mg/kg; p.o.; daily; 12 months) sodium salt causes interstitial nephritis in monkeys[3].
Zomepirac (p.o.; daily; 24 months) sodium salt increases the incidence of adrenal tumours and hyperplasia in rats[3].
Zomepirac (p.o.; daily; 18 months) sodium salt does not cause carcinogenicity in mice[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Mice (Naloxone challenge jumping model)[3]
Dosage: 5 mg/kg
Administration: p.o.; 3 times daily; 3 days
Result: Showed no jumping after naloxone challenge, whereas morphine-pretreated mice showed significant jumping behavior.
Animal Model: Cats[3]
Dosage: 0.3 mg/kg; 3 mg/kg
Administration: i.v.
Result: Reduced cerebrospinal fluid immunoreactive prostaglandin E2 concentrations by approximately 96%.
Concentrations remained depressed for up to 5 days and returned to control values within 7 days.
Animal Model: Monkeys[3]
Dosage: 2 mg/kg; 6 mg/kg
Administration: i.v.
Result: Produced a substantial reduction in spinothalamic tract cell responses to mechanical, thermal, and algesic chemical stimuli.
Animal Model: Monkeys[3]
Dosage: 20 mg/kg
Administration: i.v.
Result: Had little effect on renal blood flow, and no effect on inulin clearance or urinary excretion of sodium and potassium.
Animal Model: Monkeys[3]
Dosage: 10 mg/kg; 40 mg/kg
Administration: p.o.; daily for 12 months
Result: Caused multifocal nephritis characterised by interstitial scarring at 40 mg/kg daily; caused milder interstitial nephritis and oedema at 10 mg/kg daily.
Molecular Weight

313.71

Formula

C15H13ClNNaO3
CAS No.
Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C(O[Na])CC1=CC(C)=C(C(C2=CC=C(Cl)C=C2)=O)N1C
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (318.77 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : 5 mg/mL (15.94 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.1877 mL 15.9383 mL 31.8766 mL
5 mM 0.6375 mL 3.1877 mL 6.3753 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (7.97 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (6.63 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 8.33 mg/mL (26.55 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.63%

SDS (480 KB)

COA (248 KB) HNMR (259 KB) LCMS (93 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 3.1877 mL 15.9383 mL 31.8766 mL 79.6914 mL
5 mM 0.6375 mL 3.1877 mL 6.3753 mL 15.9383 mL
10 mM 0.3188 mL 1.5938 mL 3.1877 mL 7.9691 mL
15 mM 0.2125 mL 1.0626 mL 2.1251 mL 5.3128 mL
DMSO 20 mM 0.1594 mL 0.7969 mL 1.5938 mL 3.9846 mL
25 mM 0.1275 mL 0.6375 mL 1.2751 mL 3.1877 mL
30 mM 0.1063 mL 0.5313 mL 1.0626 mL 2.6564 mL
40 mM 0.0797 mL 0.3985 mL 0.7969 mL 1.9923 mL
50 mM 0.0638 mL 0.3188 mL 0.6375 mL 1.5938 mL
60 mM 0.0531 mL 0.2656 mL 0.5313 mL 1.3282 mL
80 mM 0.0398 mL 0.1992 mL 0.3985 mL 0.9961 mL
100 mM 0.0319 mL 0.1594 mL 0.3188 mL 0.7969 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Zomepirac sodium salt Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Zomepirac64092-48-4McN-2783-21-98PGE synthaseProstaglandin E synthasemiceopiate receptorsratsprostaglandin synthetaseprostaglandin synthesishuman serum albuminhuman plasma albuminplatelet aggregationacyl glucuronide metabolitesrhesus monkeysInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Zomepirac sodium salt
Cat. No.:
HY-B0890
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (480 KB) Français - FR (480 KB) Deutsch - DE (480 KB) Norwegian - NO (480 KB) Español - ES (480 KB) Swedish - SV (480 KB) Italian - IT (480 KB) Korean - KR (480 KB) Portuguese - PT (480 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.